NASDAQ · Biotechnology

Iterum Therapeutics plc (ITRM) Stock

$0.03 -10.98% NASDAQ: ITRM Healthcare

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States.

Valuation

MetricValue
Price$0.03
Market Cap$1.60M
P/E Ratio-0.06
P/B Ratio-0.19
P/S Ratio4.10
EPS (TTM)$-1.26
52-Week High$1.42
52-Week Low$0.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE442.32%
ROA-62.70%
ROCE-63.75%
Gross Margin-171.28%
Operating Margin—
Net Margin—
Debt/Equity-4.57
Current Ratio2.13

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-32.0M$-25.0M$-30.0M$-47.0M$-19.0M
Net Profit$-52.0M$-92.0M$-44.0M$-38.0M$-25.0M
EPS$-32.49$-8.41$-3.63$-2.96$-1.26
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$33.0M$92.0M$67.0M$26.0M$45.0M
Total Liabilities$83.0M$41.0M$39.0M$33.0M$49.0M
Cash$15.0M$27.0M$21.0M$6.0M$24.0M
Borrowings$48.0M$30.0M$30.0M$19.0M$46.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-55.0M$-16.0M$-18.0M$-39.0M$-27.0M
Investing Cash Flow$0$-55.0M$14.0M$23.0M$18.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$10.0M$13.0M$-6.0M$-15.0M$18.0M
Free Cash Flow$-55.0M$-16.0M$-19.0M$-39.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.38
FCF Yield-980.34%
Quick Ratio1.96
Interest Coverage-11.67
Return 1Y—
Return 3Y—
Return 5Y—

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.

Iterum Therapeutics plc is headquartered in IE.

Iterum Therapeutics plc (ITRM) stock trades at $0.03 with a market capitalization of $1.60M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.06, reflecting a net loss over the last twelve months, a negative price-to-book of -0.19, reflecting negative shareholders' equity, price-to-sales of 4.10. Over the past 52 weeks the stock has ranged between $0.03 and $1.42, and currently trades 97.9% below its 52-week high.

On profitability, Iterum Therapeutics plc generates a return on equity (ROE) of 442.32% (not meaningful, as shareholders' equity is negative), return on capital employed of -63.75%.

Official website: www.iterumtx.com

Iterum Therapeutics plc by the numbers, 2016–2024

Between 2016 and 2024 Iterum Therapeutics plc reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-25.0M.

On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-28.0M.

Borrowings stand at $46.0M, cash on hand is $11.0M, cash from operations was $-27.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged 203.8% over five years, and was 625.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Iterum Therapeutics plc (ITRM) — frequently asked questions

What is Iterum Therapeutics plc (ITRM) stock price today?

Iterum Therapeutics plc (ITRM) is currently trading at $0.03, down 10.98% today.

What is ITRM P/E ratio?

Iterum Therapeutics plc's P/E ratio is -0.06. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ITRM return on equity (ROE)?

Iterum Therapeutics plc's return on equity (ROE) is 442.32%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Iterum Therapeutics plc's market cap?

Iterum Therapeutics plc has a market capitalization of $1.60M.

Does ITRM pay a dividend?

Iterum Therapeutics plc is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does ITRM carry?

Iterum Therapeutics plc has a debt-to-equity ratio of -4.57. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What sector is ITRM in?

Iterum Therapeutics plc is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ITRM listed on?

Iterum Therapeutics plc trades on NASDAQ under the ticker ITRM.

What is ITRM's 52-week range?

Over the last year Iterum Therapeutics plc has traded between $0.03 and $1.42.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens ITRM currently matches

On the figures above, Iterum Therapeutics plc passes the filters for 3 of our ready-made screens, among them Day Losers Stocks, Stocks Under $1, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Day Losers StocksStocks Under $1Nano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.